{"&cites=12674526305022444340&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa066838","authors":["G Hudes","G Hudes M Carducci","G Hudes M Carducci P Tomczak…"],"year":2007,"numCitations":4021,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa066838","citationUrl":"http://scholar.google.com/scholar?cites=11854457709475007825&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:UQ0mqnp-g6QJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11854457709475007825&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596898396283},{"title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673608610399","authors":["RJ Motzer","RJ Motzer B Escudier","RJ Motzer B Escudier S Oudard","RJ Motzer B Escudier S Oudard TE Hutson","RJ Motzer B Escudier S Oudard TE Hutson C Porta…"],"year":2008,"numCitations":3182,"pdf":"http://www.academia.edu/download/53999404/s0140-6736_2808_2961039-920170728-7660-zx8w1m.pdf","citationUrl":"http://scholar.google.com/scholar?cites=8449425975912964334&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:7iBAeihkQnUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8449425975912964334&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673607619047","authors":["B Escudier","B Escudier A Pluzanska","B Escudier A Pluzanska P Koralewski","B Escudier A Pluzanska P Koralewski A Ravaud…"],"year":2007,"numCitations":2570,"pdf":"https://journals.viamedica.pl/nowotwory_journal_of_oncology/article/download/52342/39075","citationUrl":"http://scholar.google.com/scholar?cites=5427817888518646484&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:1Cqqnpx7U0sJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5427817888518646484&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","url":"http://s-space.snu.ac.kr/handle/10371/77398","authors":["CN Sternberg","CN Sternberg ID Davis","CN Sternberg ID Davis J Mardiak…"],"year":2010,"numCitations":2448,"pdf":"http://s-space.snu.ac.kr/bitstream/10371/77398/1/Sternberg-2010-Pazopanib%20in%20Locally.pdf","citationUrl":"http://scholar.google.com/scholar?cites=17868513553253356300&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:DFPrvWe2-fcJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=17868513553253356300&hl=en&as_sdt=2005&sciodt=0,5","publication":"s-space.snu.ac.kr"},{"title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3646307/","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2009,"numCitations":2287,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3646307/","citationUrl":"http://scholar.google.com/scholar?cites=9930987091739607833&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:GQMhsCT00YkJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9930987091739607833&hl=en&as_sdt=2005&sciodt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"EAU guidelines on renal cell carcinoma: 2014 update","url":"https://www.sciencedirect.com/science/article/pii/S0302283815000196","authors":["B Ljungberg","B Ljungberg K Bensalah","B Ljungberg K Bensalah S Canfield","B Ljungberg K Bensalah S Canfield S Dabestani…"],"year":2015,"numCitations":1787,"pdf":"http://rihuc.huc.min-saude.pt/bitstream/10400.4/1818/1/renal%20cell%20carcinoma.pdf","citationUrl":"http://scholar.google.com/scholar?cites=16069395757100116624&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:kCofQU32Ad8J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16069395757100116624&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","url":"https://www.nature.com/articles/nrc2403?cacheBust=1508158330423","authors":["LM Ellis","LM Ellis DJ Hicklin"],"year":2008,"numCitations":1693,"citationUrl":"http://scholar.google.com/scholar?cites=18235633363190911599&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:b5JBY-37Ef0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=18235633363190911599&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673611616139","authors":["BI Rini","BI Rini B Escudier","BI Rini B Escudier P Tomczak","BI Rini B Escudier P Tomczak A Kaprin","BI Rini B Escudier P Tomczak A Kaprin C Szczylik…"],"year":2011,"numCitations":1695,"citationUrl":"http://scholar.google.com/scholar?cites=3547505814206124423&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:h5FjFr5FOzEJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3547505814206124423&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results …","url":"https://confkhalifa.com/trainingkhalifa/wp-content/uploads/2017/05/DP-2-LCA-ARTICLE-The%CC%81o-PEZEL-CB-avril-2017-anglais.pdf","authors":["DYC Heng","DYC Heng W Xie","DYC Heng W Xie MM Regan","DYC Heng W Xie MM Regan MA Warren…"],"year":2009,"numCitations":1433,"pdf":"https://confkhalifa.com/trainingkhalifa/wp-content/uploads/2017/05/DP-2-LCA-ARTICLE-The%CC%81o-PEZEL-CB-avril-2017-anglais.pdf","citationUrl":"http://scholar.google.com/scholar?cites=4181130477325190870&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:1gaHPARcBjoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4181130477325190870&hl=en&as_sdt=2005&sciodt=0,5","publication":"confkhalifa.com"},{"title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1303989","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson D Cella","RJ Motzer TE Hutson D Cella J Reeves…"],"year":2013,"numCitations":1434,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1303989","citationUrl":"http://scholar.google.com/scholar?cites=5593415504868596567&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:V9vaOMTNn00J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5593415504868596567&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"}]}